MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022
By LabMedica International staff writers Posted on 15 Nov 2022 |
MP Biomedicals (Eschwege, Germany) is exhibiting its wide product portfolio of POC, screening and confirmatory tests, backed by a range of testing methods that aid in the diagnosis, detection, and recovery from diseases, at MEDICA 2022.
At this year’s edition of MEDICA, MP Biomedicals is exhibiting the AutoBlot System 36, an intelligent Western Blot processor that enables automated washing and incubation of up to 36 assay strips per run at a pre-selected temperature. The AutoBlot System 36 helps to satisfy Immunoblot needs by minimizing human error, increasing productivity and delivering accurate and consistent results. MP Biomedicals is also showcasing its innovative diagnostic tests such as the Rapid SARS-CoV-2 Antigen Test Card, an IVD test for private use to detect SARS-CoV-2 antigens from anterior nasal swabs, alongside the Rapid 2019-nCoV IgG/IgM Combo Test Card, which is an immunochromatography based one-step in vitro test designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV,SARS-CoV-2) in human serum, plasma, or whole blood.
MP Biomedicals is also highlighting its POC testing and screening solutions for the qualitative assessment of drugs and their metabolites in human urine and saliva. Visitors to the MP Biomedicals booth at MEDICA 2022 can gain insights into the MP Diagnostics HIV BLOT 2.2 qualitative enzyme immunoassay for the in vitro detection of antibodies to human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) in human serum or plasma. HIV BLOT 2.2 is intended for use as a more specific supplemental test on human serum or plasma specimens found repeatedly reactive using screening procedures such as the Enzyme-Linked Immunosorbent Assay (ELISA). Also on display at the event is the MP Diagnostics MULTISURE HIV 1/2 Confirmatory Test for use as a rapid confirmatory test to detect and differentiate antibodies specific to HIV-1 gp120, HIV-1 gp41, HIV-1 p24 and HIV-2 gp36, HIV-2 gp105 antigens in human serum or plasma.
Related Links:
MP Biomedicals
Latest MEDICA 2022 News
- Bosch Demonstrates Vivalytic All-In-One PCR Analyzer at MEDICA 2022
- Biovendor Group Presents CLIA Solution for Complex Diagnostics at MEDICA 2022
- Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022
- Immundiagnostik AG Presents New PCR Test MutaPLEX RespiraScreen4_Diff_seqc at MEDICA 2022
- Eurotrol Presents the Future of Blood Gas Controls at MEDICA 2022
- Rhinomed Announces European Launch of Revolutionary New Swab for Testing Children for Respiratory Diseases
- Absology Exhibits POCT Immunoassay Analyzer with Testing Time of Five Minutes
- Cormay Diagnostics Introduces True 5+ DIFF Multi-Patented Hematology Solution at MEDICA 2022
- EDAN Takes its Solutions up a Notch at MEDICA 2022
- Bioneer Presents Near-Patient POC Molecular Diagnostic System at MEDICA 2022
- Rhinostics Features New RHINObot Automated Decapper at MEDICA 2022
- Oxford Immunotec Showcases Automated T-SPOT.TB Test at MEDICA 2022
- Boditech Highlights Automated Benchtop and Handheld Immunoassay Readers at MEDICA 2022
- Co-Diagnostics Introduces its CoPrimer Technology and Applications at MEDICA 2022
- Sentinel Diagnostics Presents New Fully Automated Sample to Result System for Diagnosis of Viral Infections
- Serosep Exhibits EntericBio System for Testing, Detecting and Identifying GI Pathogens at MEDICA 2022